Danaher (DHR) Stock Falls 9% After Q3 Revenue Guidance Disappoints

TLDR

• Danaher beat Q2 estimates with EPS of $1.94 vs. $1.84 expected and revenue of $6.3B vs. $6.1B expected
• Stock fell 9% premarket despite the earnings beat
• Q3 core revenue growth guided at just 2–3%, which disappointed investors
• Full-year 2026 core revenue growth guided at 3–4%; adjusted EPS guidance raised to $8.45–$8.60
• Life Sciences segment posted its strongest quarter in several years; bioprocessing orders grew mid-teens

---

Danaher (DHR) stock dropped 9% in premarket trading on Tuesday after the company’s Q3 growth outlook came in below what investors were hoping for — even as Q2 results cleared the bar comfortably.

Danaher Corporation, DHR

Adjusted EPS came in at $1.94, beating the $1.84 consensus by $0.10. Revenue hit $6.3 billion, topping the $6.1 billion estimate and marking a 5.5% year-over-year increase.

Core revenue grew 3.0% year-over-year. Excluding respiratory testing revenue, that figure rises to 4.5%.

DANAHER $DHR Q2’26 EARNINGS HIGHLIGHTS

🔹 Revenue: $6.3B (Est. $6.27B) 🟡; +5.5% YoY
🔹 Adj. EPS: $1.94 (Est. $1.84) 🟢; +8.0% YoY
🔹 FCF: $1.3B; +~15.5% YoY

Raises FY26 Guide:
🔹 Adj. EPS: $8.45-$8.60 (Est. $8.5) 🟡
🔹 Core Revenue Growth: +3.0%-+4.0%

Segment Revenue:
🔹… pic.twitter.com/Tjhwvwzahk

— Wall St Engine (@wallstengine) July 21, 2026

The problem wasn’t the quarter — it was what comes next.

Danaher guided Q3 core revenue growth at 2–3%, a range that fell short of investor expectations. For the full year 2026, the company sees core revenue growth of 3–4%.

On the earnings side, full-year 2026 adjusted EPS guidance was raised to $8.45–$8.60, up from the prior range of $8.35–$8.55. The midpoint of $8.53 edges just above the analyst consensus of $8.50.

CEO Rainer Blair called it “a better than expected second quarter,” pointing to improving core growth versus Q1 and high-single-digit adjusted EPS growth.

Segment Breakdown

Life Sciences was the standout, posting 5.5% core revenue growth — its strongest quarter in several years, according to management. Biotechnology grew 2.5% and Diagnostics added 2.0%.

Bioprocessing revenue was impacted by customer project timing, but Blair noted that underlying order trends stayed strong, with bioprocessing orders growing mid-teens in the quarter.

Operating cash flow came in at $1.5 billion for Q2. Free cash flow reached $1.3 billion.

What’s Weighing on the Stock

The modest Q3 guidance range appears to be the key trigger for the selloff. Investors had priced in more acceleration, and a 2–3% core growth outlook doesn’t clear that bar.

Pricing pressure in China’s diagnostics market and uneven equipment demand are factors that could add friction to growth. Timing issues in quarterly revenue have also made results choppy, which keeps the stock sensitive to guidance misses.

Year-to-date, DHR is down 11.78% heading into today’s session.

The market cap stands at approximately $144.3 billion, with an average daily trading volume of around 4.6 million shares.